Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan

Masamitsu Yanada, Akiyoshi Takami, Shohei Mizuno, Jinichi Mori, Takaaki Chou, Kensuke Usuki, Hitoji Uchiyama, Itsuto Amano, Shiro Fujii, Toshihiro Miyamoto, Takeshi Saito, Tomohiko Kamimura, Tatsuo Ichinohe, Takahiro Fukuda, Shinichiro Okamoto, Yoshiko Atsuta, Shingo Yano

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual number of transplantations peaked at 82 cases in 1997, and has recently remained at around 40 cases. The percentage of APL has increased sharply since 2004, and currently exceeds 70%. While most non-APL patients underwent autologous HCT during first complete remission (CR), transplantation during second CR has become mainstream for APL patients since the early 2000s. The 5-year survival, relapse, and non-relapse mortality rates were 55.3%, 42.1%, and 8.6% for non-APL patients, and 87.6%, 12.9%, and 3.4% for APL patients, respectively. Patients transplanted in the later period showed better survival than those transplanted in the earlier period, both for non-APL (P < 0.001) and APL (P = 0.036). These results clearly show the various changes in transplantation practice and post-transplant outcomes in Japan over the past 25 years.

元の言語英語
ページ(範囲)93-102
ページ数10
ジャーナルInternational journal of hematology
111
発行部数1
DOI
出版物ステータス出版済み - 1 1 2020

Fingerprint

Cell Transplantation
Acute Promyelocytic Leukemia
Acute Myeloid Leukemia
Japan
Transplantation
Leukemia
Survival
Registries
Transplants
Recurrence
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults : 25 years of experience in Japan. / Yanada, Masamitsu; Takami, Akiyoshi; Mizuno, Shohei; Mori, Jinichi; Chou, Takaaki; Usuki, Kensuke; Uchiyama, Hitoji; Amano, Itsuto; Fujii, Shiro; Miyamoto, Toshihiro; Saito, Takeshi; Kamimura, Tomohiko; Ichinohe, Tatsuo; Fukuda, Takahiro; Okamoto, Shinichiro; Atsuta, Yoshiko; Yano, Shingo.

:: International journal of hematology, 巻 111, 番号 1, 01.01.2020, p. 93-102.

研究成果: ジャーナルへの寄稿記事

Yanada, M, Takami, A, Mizuno, S, Mori, J, Chou, T, Usuki, K, Uchiyama, H, Amano, I, Fujii, S, Miyamoto, T, Saito, T, Kamimura, T, Ichinohe, T, Fukuda, T, Okamoto, S, Atsuta, Y & Yano, S 2020, 'Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan', International journal of hematology, 巻. 111, 番号 1, pp. 93-102. https://doi.org/10.1007/s12185-019-02759-y
Yanada, Masamitsu ; Takami, Akiyoshi ; Mizuno, Shohei ; Mori, Jinichi ; Chou, Takaaki ; Usuki, Kensuke ; Uchiyama, Hitoji ; Amano, Itsuto ; Fujii, Shiro ; Miyamoto, Toshihiro ; Saito, Takeshi ; Kamimura, Tomohiko ; Ichinohe, Tatsuo ; Fukuda, Takahiro ; Okamoto, Shinichiro ; Atsuta, Yoshiko ; Yano, Shingo. / Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults : 25 years of experience in Japan. :: International journal of hematology. 2020 ; 巻 111, 番号 1. pp. 93-102.
@article{13452b7d812f4e13bef5fabafb9d2f44,
title = "Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan",
abstract = "Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual number of transplantations peaked at 82 cases in 1997, and has recently remained at around 40 cases. The percentage of APL has increased sharply since 2004, and currently exceeds 70{\%}. While most non-APL patients underwent autologous HCT during first complete remission (CR), transplantation during second CR has become mainstream for APL patients since the early 2000s. The 5-year survival, relapse, and non-relapse mortality rates were 55.3{\%}, 42.1{\%}, and 8.6{\%} for non-APL patients, and 87.6{\%}, 12.9{\%}, and 3.4{\%} for APL patients, respectively. Patients transplanted in the later period showed better survival than those transplanted in the earlier period, both for non-APL (P < 0.001) and APL (P = 0.036). These results clearly show the various changes in transplantation practice and post-transplant outcomes in Japan over the past 25 years.",
author = "Masamitsu Yanada and Akiyoshi Takami and Shohei Mizuno and Jinichi Mori and Takaaki Chou and Kensuke Usuki and Hitoji Uchiyama and Itsuto Amano and Shiro Fujii and Toshihiro Miyamoto and Takeshi Saito and Tomohiko Kamimura and Tatsuo Ichinohe and Takahiro Fukuda and Shinichiro Okamoto and Yoshiko Atsuta and Shingo Yano",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s12185-019-02759-y",
language = "English",
volume = "111",
pages = "93--102",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults

T2 - 25 years of experience in Japan

AU - Yanada, Masamitsu

AU - Takami, Akiyoshi

AU - Mizuno, Shohei

AU - Mori, Jinichi

AU - Chou, Takaaki

AU - Usuki, Kensuke

AU - Uchiyama, Hitoji

AU - Amano, Itsuto

AU - Fujii, Shiro

AU - Miyamoto, Toshihiro

AU - Saito, Takeshi

AU - Kamimura, Tomohiko

AU - Ichinohe, Tatsuo

AU - Fukuda, Takahiro

AU - Okamoto, Shinichiro

AU - Atsuta, Yoshiko

AU - Yano, Shingo

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual number of transplantations peaked at 82 cases in 1997, and has recently remained at around 40 cases. The percentage of APL has increased sharply since 2004, and currently exceeds 70%. While most non-APL patients underwent autologous HCT during first complete remission (CR), transplantation during second CR has become mainstream for APL patients since the early 2000s. The 5-year survival, relapse, and non-relapse mortality rates were 55.3%, 42.1%, and 8.6% for non-APL patients, and 87.6%, 12.9%, and 3.4% for APL patients, respectively. Patients transplanted in the later period showed better survival than those transplanted in the earlier period, both for non-APL (P < 0.001) and APL (P = 0.036). These results clearly show the various changes in transplantation practice and post-transplant outcomes in Japan over the past 25 years.

AB - Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual number of transplantations peaked at 82 cases in 1997, and has recently remained at around 40 cases. The percentage of APL has increased sharply since 2004, and currently exceeds 70%. While most non-APL patients underwent autologous HCT during first complete remission (CR), transplantation during second CR has become mainstream for APL patients since the early 2000s. The 5-year survival, relapse, and non-relapse mortality rates were 55.3%, 42.1%, and 8.6% for non-APL patients, and 87.6%, 12.9%, and 3.4% for APL patients, respectively. Patients transplanted in the later period showed better survival than those transplanted in the earlier period, both for non-APL (P < 0.001) and APL (P = 0.036). These results clearly show the various changes in transplantation practice and post-transplant outcomes in Japan over the past 25 years.

UR - http://www.scopus.com/inward/record.url?scp=85074014829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074014829&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02759-y

DO - 10.1007/s12185-019-02759-y

M3 - Article

C2 - 31612307

AN - SCOPUS:85074014829

VL - 111

SP - 93

EP - 102

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -